Blood Gene Expression Profiling of Neurologic Diseases: A Pilot Microarray Study

ArticleinJAMA Neurology 62(2):210-5 · March 2005with6 Reads
Impact Factor: 7.42 · DOI: 10.1001/archneur.62.2.210 · Source: PubMed


    Tissue gene expression profiling with arrays measures the transcription of thousands of genes. However, this approach cannot be readily used to guide clinical neurologic practice.
    To determine whether clinical neurologic diseases are associated with unique patterns of up- and down-regulated genes in whole blood and to explore the possibility of using peripheral blood as a surrogate tissue in these diseases.
    Case-control study.
    University-based pediatric and adult neurology clinics.
    Patients with neurofibromatosis type 1, epilepsy, or Tourette syndrome diagnosed using traditional clinical criteria; controls without disease; and controls with neurologic disease.
    Blood gene expression levels of greater than 12,000 genes, measured using U95A arrays.
    Neurofibromatosis type 1 and childhood epilepsy treated with carbamazepine or valproic acid are associated with distinct patterns of blood gene expression. Patients with valproic acid-responsive vs valproic acid-refractory epilepsy formed distinct subclusters. Tourette syndrome was characterized by several gene expression clusters. In 1 cluster, 6 genes-all associated with immune cell function-were overexpressed.
    Blood gene expression profiling can provide surrogate markers for neurologic diseases without obvious blood phenotypes.